Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 10;23(12):6501. doi: 10.3390/ijms23126501

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Orlistat combined with sorafenib significantly increased cell killing effects on Huh7 and Huh7/SR cells. (A) Cell viability of both cell lines was assessed by MTT assay after being treated with sorafenib combined with or without 50 µM orlistat. Huh7/SR cells had higher cell viability than Huh7 cells when treated with sorafenib alone (>10 µM). However, the combination treatment resulted in comparable cell killing in both cell lines. (B) Cell cycle distribution was evaluated by flow cytometry. Combination treatment remarkably increased the sub-G1 population in both cell lines, and the effect was more evident in Huh7/SR cells than in Huh7 cells. Besides, combination treatment caused a more significant G2/M reduction in Huh7/SR cells than in Huh7 cells.